A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster Associated Pain

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster Associated Pain

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Valnivudine (Primary)
  • Indications Herpes zoster; Postherpetic neuralgia
  • Focus Registrational; Therapeutic Use
  • Sponsors ContraVir Pharmaceuticals
  • Most Recent Events

    • 16 Jun 2016 According to ContraVir Pharmaceuticals media release, the company has anounced that it has amended the clinical trial protocol of this trial to more accurately represent the changing shingles population as seen in clinical practice and enroll the most clinically relevant patients into the study.
    • 15 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2017.
    • 15 Apr 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top